Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor
Aandeel

RELIEF THERAPEUTICS N CH1251125998

Laatste koers (chf)

3,290

  • Verschil

    -0,110 -3,24%

  • Volume

    22.370 Gem. (3M) 66,5K

  • Bied

    3,210  

  • Laat

    3,350  
+ In watchlist

Relief therapeutics Holding

9.105 Posts
Pagina: «« 1 ... 444 445 446 447 448 ... 456 »» | Laatste | Omlaag ↓
  1. RodgerRodger 8 februari 2022 07:33

    • RodgerRodger

      Lid sinds: 03 dec 2007

      Laatste bezoek: 06 feb 2025

    • Aanbevelingen

      Ontvangen: 188

      Gegeven: 1097

    •    Aantal posts: 555

    gateway.eqs.com/maily/online-version/...
    Dear Sir or Madam,

    We would like to draw your attention to the following ad hoc announcement pursuant to Art. 53 LR of RELIEF THERAPEUTICS Holding SA:

    Relief Files Trademark Application for RLF-100™ With the U.S. Patent and Trademark Office

    No Notice of Opposition or Extension Request has Been Received in Relation to the Application; Certificate of Registration Expected by Late April.

    Geneva, Switzerland, February 8, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced that it is has filed for a trademark for RLF-100™ with the United States Patent and Trademark Office (“USPTO”).

    When the certificate of registration is received, the trademark will cover RLF-100TM when used for pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations for the treatment of viral diseases and; pharmaceutical preparations for the treatment of viral infections.

    The trademark application (U.S. Serial Number 90141290) filed on August 27, 2020 was published for opposition on January 4, 2022. No party has filed an opposition or extension request with the USPTO within the required 30 days after the publication date. A certificate of registration is expected to be issued to Relief within 11 weeks from the publication date.
  2. forum rang 10 DeZwarteRidder 8 februari 2022 08:21

    • DeZwarteRidder

      Lid sinds: 29 jun 2012

      Laatste bezoek: 08 feb 2025

    • Aanbevelingen

      Ontvangen: 24059

      Gegeven: 10520

    •    Aantal posts: 101.952

    Weer een f(l)opbericht........!!!!

    Ondertussen is NRX met ca 75% gedaald sinds de IPO.

    Dit geeft wel aan dat ze zelfs in de USA er niet meer in geloven.
  3. Ronduit 15 februari 2022 09:13

    • Ronduit

      Lid sinds: 18 feb 2020

      Laatste bezoek: 30 jan 2025

    • Aanbevelingen

      Ontvangen: 41

      Gegeven: 44

    •    Aantal posts: 257

    Weet iemand een site waar dit aandeel live te volgen is? Het 'trucje' met een limit order zetten ken ik, maar zou graag de koers ook live willen volgen.
  4. forum rang 10 DeZwarteRidder 15 februari 2022 09:18

    • DeZwarteRidder

      Lid sinds: 29 jun 2012

      Laatste bezoek: 08 feb 2025

    • Aanbevelingen

      Ontvangen: 24059

      Gegeven: 10520

    •    Aantal posts: 101.952

    quote:

    Ronduit schreef op 15 februari 2022 09:13:

    Weet iemand een site waar dit aandeel live te volgen is? Het 'trucje' met een limit order zetten ken ik, maar zou graag de koers ook live willen volgen.
    Vergeet het maar.
  6. RodgerRodger 16 februari 2022 08:52

    • RodgerRodger

      Lid sinds: 03 dec 2007

      Laatste bezoek: 06 feb 2025

    • Aanbevelingen

      Ontvangen: 188

      Gegeven: 1097

    •    Aantal posts: 555

    Relief: NRx kommt mit Corona-Studie in den USA weiter
    Name Markt Letzter Veränderung
    RELIEF THERAPEUTICS N SIX 0.07 -

    < >
    Genf (awp) - Das Biotechunternehmen Relief Therapeutics berichtet, dass das US-Unternehmen NRx Pharmaceuticals mit der Patientenrekrutierung für seine Phase-III-Studie ACTIV-3b fortfahren darf. So habe das Datenüberwachungskomitee (DSMB, Data Safety Monitoring Board) die Daten von 448 Intensivpatienten mit kritischer Covid-19-Ateminsuffizienz begutachtet, die in die Studie aufgenommen wurden, teilte Relief unter Verweis auf eine NR-Mitteilung am Mittwoch mit.

    In der Behandlung mit Zyesami (Aviptadil) seien dabei keine neuen Sicherheitsbedenken festgestellt worden und die Studie sei nun für eine weitere Aufnahme von 640 Patienten freigegeben.

    Zudem sei ein weiteres Protokoll der Studie eingereicht und von der US-Zulassungsbehörde FDA als Phase-III-Studie anerkannt worden. Diese könne damit im Falle eines positiven Ergebnisses für die Einreichung eines neuen Zulassungsantrags für Zyesami verwendet werden kann.

    hr/rw
  7. forum rang 10 DeZwarteRidder 16 februari 2022 08:59

    • DeZwarteRidder

      Lid sinds: 29 jun 2012

      Laatste bezoek: 08 feb 2025

    • Aanbevelingen

      Ontvangen: 24059

      Gegeven: 10520

    •    Aantal posts: 101.952

    quote:

    RodgerRodger schreef op 16 februari 2022 08:52:

    Relief: NRx kommt mit Corona-Studie in den USA weiter
    Name Markt Letzter Veränderung
    RELIEF THERAPEUTICS N SIX 0.07
    < >
    Genf (awp) - Das Biotechunternehmen Relief Therapeutics berichtet, dass das US-Unternehmen NRx Pharmaceuticals mit der Patientenrekrutierung für seine Phase-III-Studie ACTIV-3b fortfahren darf. So habe das Datenüberwachungskomitee (DSMB, Data Safety Monitoring Board) die Daten von 448 Intensivpatienten mit kritischer Covid-19-Ateminsuffizienz begutachtet, die in die Studie aufgenommen wurden, teilte Relief unter Verweis auf eine NR-Mitteilung am Mittwoch mit.

    In der Behandlung mit Zyesami (Aviptadil) seien dabei keine neuen Sicherheitsbedenken festgestellt worden und die Studie sei nun für eine weitere Aufnahme von 640 Patienten freigegeben.

    Zudem sei ein weiteres Protokoll der Studie eingereicht und von der US-Zulassungsbehörde FDA als Phase-III-Studie anerkannt worden. Diese könne damit im Falle eines positiven Ergebnisses für die Einreichung eines neuen Zulassungsantrags für Zyesami verwendet werden kann.
    hr/rw
    Mooi op tijd........!!!
  13. [verwijderd] 13 maart 2022 23:23

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    DeZwarteRidder schreef op 9 maart 2022 07:52:

    [...]
    Het werd hoog tijd dat deze oen ontslagen werd, want hij is verantwoordelijk voor een koersdaling van ca 80%.
    Hiermee heb je voor de eerste keer een duimpje op gehad ;-)
  18. forum rang 10 DeZwarteRidder 31 maart 2022 22:16

    • DeZwarteRidder

      Lid sinds: 29 jun 2012

      Laatste bezoek: 08 feb 2025

    • Aanbevelingen

      Ontvangen: 24059

      Gegeven: 10520

    •    Aantal posts: 101.952

    NRx

    Financial Results for the Year Ended December 31, 2021

    Research and development expenses for the year ended December 31, 2021, totaled $20.3 million, compared to $10.6 million for the year ended December 31, 2020. The increase was primarily driven by an increase in clinical trials and development expenses related to ZYESAMI®.
    General and administrative expenses for the year ended December 31, 2021, totaled $74.9 million, of which $60.3 million were non-cash stock-based compensation, consulting fees and warrant expense. General and administrative expenses for the year ended December 31, 2020, totaled $11.4 million, of which $5.7 million was non-cash stock-based compensation, consulting fees, and warrant expense. The increase was primarily due to the increase in non-cash stock-based compensation expenses, consulting fees, and an increase in insurance expenses.
    Settlement expense for the year ended December 31, 2021, was $21.4 million compared to $39.5 million for the year ended December 31, 2020. Settlement expense is a non-cash expense.
    Reimbursements of expenses from Relief Therapeutics were $0.8 million for the year ended December 31, 2021, compared to $10.2 million for the year ended December 31, 2020.
    Other income for the year ended December 31, 2021, was $22.7 million, driven primarily by a $20.9 million decrease in the earnout cash liability and a $1.7 million decrease in the warrant liability. Other expenses for the year ended December 31, 2020, were $0.4 million primarily due to a loss on conversion of convertible notes payable.
    Net loss for the year ended December 31, 2021, was $93.1 million, or $1.98 per share, compared with a net loss of $51.8 million, or $1.51 per share for the year ended December 31, 2020.
    Cash used in operating activities was $37.7 million for the year ended December 31, 2021, compared to $2.3 million for the year ended December 31, 2020.
    As of December 31, 2021, cash was $27.6 million, compared to $1.9 million as of December 31, 2020. As previously mentioned, NRx completed a $25 million private placement financing in February 2022. NRx believes it has sufficient cash to support operations for at least the next 12 months.
  20. forum rang 10 DeZwarteRidder 1 april 2022 07:46

    • DeZwarteRidder

      Lid sinds: 29 jun 2012

      Laatste bezoek: 08 feb 2025

    • Aanbevelingen

      Ontvangen: 24059

      Gegeven: 10520

    •    Aantal posts: 101.952

    quote:

    RodgerRodger schreef op 1 april 2022 07:18:

    relieftherapeutics.com/newsblog-detai...
    Collaboration Partner has Announced that the I-SPY COVID Trial Suggests No Clinical Benefit with Addition of Nebulized Aviptadil in Critically Ill Patients with COVID-19

    Relief Therapeutics Holding SA / Key word(s): Study

    01-Apr-2022 / 07:00 CET/CEST
    Release of an ad hoc announcement pursuant to Art. 53 LR
    The issuer is solely responsible for the content of this announcement.

    Relief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Suggests No Clinical Benefit with Addition of Nebulized Aviptadil When Given by Mouth Inhalation in Critically Ill Patients with COVID-19

    Geneva, Switzerland, April 1, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company, NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx"), of its collaboration partner with respect to aviptadil, NeuroRx, Inc. ("NeuroRx"), and Quantum Leap Healthcare Collaborative ("QLHC"), have announced that the nebulized form of aviptadil being used in the I-SPY COVID Trial of critical COVID-19 patients has been stopped. According to NRx and QLHC, the I-SPY COVID Trial (NCT04488081) is a phase 2, open label, adaptive platform trial designed to rapidly screen potential agents that could substantially improve treatment for severely and critically ill COVID-19 patients. QLHC is the sponsor of the I-SPY COVID Trial. NRx and QLHC reported that the trial is structured to identify those agents with a big impact, those that could have the potential to reduce the time to recovery (defined as reduction in oxygen demand) by approximately 50% or risk of mortality in critically ill COVID-19 patients. The related NRx and QLHC press release can be accessed through the following link.

9.105 Posts
Pagina: «« 1 ... 444 445 446 447 448 ... 456 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in
RELIEF THERAPEUTICS N

Van de redactie

  1. 10 afgeprijsde aandelen van topbedrijven
  2. Met deze ETF kleurt uw portefeuille groen als de S&P 500 daalt
  3. 7 koopwaardige aandelen voor de lange termijn
  4. Dit aandeel is toegevoegd aan favorietenlijstje beleggers
  5. TA-column Nico Bakker: koopkansen bij Nvidia?
  6. Twee groeiaandelen met verdubbelpotentieel in vijf jaar
Meer artikelen